Celgene investors’ CVR payment looks rocky, as FDA rejects ide-cel fileThe chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right Share XCelgene investors’ CVR payment looks rocky, as FDA rejects ide-cel filehttps://pharmaphorum.com/news/celgene-investors-merger-payment-looks-rocky-as-fda-rejects-ide-cel-file/
Saunders steps aside as AbbVie closes in on Allergan mergerThe US competition regulator has finally approved the $63 billion takeover of Allergan by AbbVie, but only by Share XSaunders steps aside as AbbVie closes in on Allergan mergerhttps://pharmaphorum.com/news/saunders-steps-aside-as-abbvie-closes-in-on-allergan-merger/
Menarini bags blood cancer drug with $677M Stemline acquisitionItalian drugmaker Menarini has agreed to buy Stemline Therapeutics, bolting on an already-approved drug for a rare form Share XMenarini bags blood cancer drug with $677M Stemline acquisitionhttps://pharmaphorum.com/news/menarini-bags-blood-cancer-drug-with-677m-stemline-acquisition/
Antitrust delay scuppers Novartis’ $1bn generics sale to AurobindoNovartis has called off the sale of two US generics businesses to India’s Aurobindo Pharma, part of a Share XAntitrust delay scuppers Novartis’ $1bn generics sale to Aurobindohttps://pharmaphorum.com/news/antitrust-delay-scuppers-novartis-1bn-generics-sale-to-aurobindo/
Lilly swoops on Dermira to claim Dupixent rivalEli Lilly agreed on Friday to buy dermatology specialist Dermira for $1.1 billion and its lead drug, a Share XLilly swoops on Dermira to claim Dupixent rivalhttps://pharmaphorum.com/news/lilly-swoops-on-dermira-to-claim-dupixent-rival/
Sumitomo, Roivant close $3 billion deal, forming SumitovantA new international biotech – Sumitovant Biopharma – has been created after Sumitomo Dainippon’s strategic alliance with Roivant Share XSumitomo, Roivant close $3 billion deal, forming Sumitovanthttps://pharmaphorum.com/news/sumitomo-roivant-close-3-billion-deal-forming-sumitovant/
Pfizer confirms generic medicines merger with MylanPfizer and Mylan have announced an all-stock deal that would combine their off-patent medicines businesses, confirming speculation that Share XPfizer confirms generic medicines merger with Mylanhttps://pharmaphorum.com/news/pfizer-confirms-generic-medicines-merger-with-mylan/
BMS will shed Otezla to push Celgene takeover throughBristol-Myers Squibb has opted to divest big-selling psoriasis drug Otezla to smooth the passage of its $74 billion Share XBMS will shed Otezla to push Celgene takeover throughhttps://pharmaphorum.com/news/bms-will-shed-otezla-to-push-celgene-takeover-through/
Sanofi steals in to buy Ablynx for €3.9 billionSanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which Share XSanofi steals in to buy Ablynx for €3.9 billionhttps://pharmaphorum.com/news/sanofi-steals-buy-ablynx-e3-9-billion/
